SERODUS ASA appoints scientific advisors for development program in Type 2 Diabetes (SER 140)

Oslo, Norway, 11 January 2016: Serodus ASA (Oslo Axess: SER), a company focusing on the development of novel treatment of cardiovascular and metabolic diseases, announces the formation of a new Scientific Advisory Board for the development program in Type 2 Diabetes (SER140).

“We are very pleased that Serodus has attracted such a high quality Scientific Advisors to guide the further development of our SER140 program. We are confidant that their advices will be invaluable”. Says Eva Steiness, CEO in Serodus.

The appointed scientific advisors for the development program are:

Prof. Richard E Pratley, MD, Florida Hospital Diabetes Institute, FL, USA

Dr. Pratley is an internationally recognized expert in diabetes and is board certified in internal medicine. He received his medical degree from Wayne State University in Detroit, and completed fellowships in geriatric medicine and gerontology at the University of Michigan, John Hopkins University, and the National Institute on Aging. As a member of the American Diabetes Association, the European Association for the Study of Diabetes and The Obesity Society, Dr. Pratley continues his active involvement in the professional community.

Professor Thomas Mandrup-Poulsen, MD, DMSc, Copenhagen University Hospital, Denmark

Thomas Mandrup-Poulsen is a physician scientist, specialist in internal medicine and endocrinology. He is a pioneer in the field of immuno-metabolism with the discovery that inflammatory cytokines impair the function and viability of pancreatic islet b-cells, for which he was awarded the 1994 Minkowski Prize of the EASD.

For additional information of a more detail biography of the scientific advisors, please visit or contact:

Tore Kvam

CFO, Serodus ASA

Mobile: +47 959 34 199


Serodus ASA is a Norwegian drug development company, focusing on new therapeutic products for the treatment of cardiovascular and metabolic diseases with large unmet clinical needs. The company's business model is to seek partnering with international pharmaceutical companies after having demonstrated clinical effect in humans. For more information see